Scientific and clinical relevance of non-cellular tumor microenvironment components in ovarian cancer chemotherapy resistance

被引:3
作者
Ostrowska-Lesko, Marta [1 ]
Rajtak, Alicja [2 ]
Moreno-Bueno, Gema [3 ,4 ,5 ]
Bobinski, Marcin [2 ]
机构
[1] Med Univ Lublin, Chair & Dept Toxicol, 8B Jaczewskiego St, PL-20090 Lublin, Poland
[2] Med Univ Lublin, Chair & Dept Oncol Gynecol & Gynecol 1, Lublin, Poland
[3] Univ Autonoma Madrid UAM, Biochem Dept, Inst Invest Biomed Sols Morreale IIBm CISC, Madrid, Spain
[4] Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
[5] Fdn MD Anderson Int FMDA, Madrid, Spain
来源
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2024年 / 1879卷 / 01期
关键词
Non-cellular components; Ovarian cancer; Tumor microenvironment; TME; Chemotherapy resistance; CARBONIC-ANHYDRASE-IX; EXTRACELLULAR-MATRIX; TENASCIN-C; CISPLATIN RESISTANCE; PACLITAXEL RESISTANCE; PLATINUM-RESISTANT; PRIMARY SURGERY; LYSYL OXIDASE; OPEN-LABEL; NEOADJUVANT CHEMOTHERAPY;
D O I
10.1016/j.bbcan.2023.189036
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The tumor microenvironment (TME) components play a crucial role in cancer cells' resistance to chemotherapeutic agents. This phenomenon is exceptionally fundamental in patients with ovarian cancer (OvCa), whose outcome depends mainly on their response to chemotherapy. Until now, most reports have focused on the role of cellular components of the TME, while less attention has been paid to the stroma and other non-cellular elements of the TME, which may play an essential role in the therapy resistance. Inhibiting these components could help define new therapeutic targets and potentially restore chemosensitivity. The aim of the present article is both to summarize the knowledge about non-cellular components of the TME in the development of OvCa chemoresistance and to suggest targeting of non-cellular elements of the TME as a valuable strategy to overcome chemoresistance and to develop new therapeutic strategies in OvCA patients.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Cellular dynamics of tumor microenvironment driving immunotherapy resistance in non-small-cell lung carcinoma
    Huang, Shujie
    Chung, Jeff Yat-Fai
    Li, Chunjie
    Wu, Yi
    Qiao, Guibin
    To, Ka-Fai
    Tang, Patrick Ming-Kuen
    CANCER LETTERS, 2024, 604
  • [32] Identification of CXCL10-Relevant Tumor Microenvironment Characterization and Clinical Outcome in Ovarian Cancer
    Jin, Jing
    Li, Yi
    Muluh, Tobias Achu
    Zhi, Liangke
    Zhao, Qijie
    FRONTIERS IN GENETICS, 2021, 12
  • [33] Single-Cell RNA Sequencing Reveals Multiple Pathways and the Tumor Microenvironment Could Lead to Chemotherapy Resistance in Cervical Cancer
    Gu, Meijia
    He, Ti
    Yuan, Yuncong
    Duan, Suling
    Li, Xin
    Shen, Chao
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [34] Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy
    Sakellariou-Thompson, Donastas
    Forget, Marie-Andree
    Hinchcliff, Emily
    Celestino, Joseph
    Hwu, Patrick
    Jazaeri, Amir A.
    Haymaker, Cara
    Bernatchez, Chantale
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (11) : 1747 - 1757
  • [35] Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy
    Donastas Sakellariou-Thompson
    Marie-Andrée Forget
    Emily Hinchcliff
    Joseph Celestino
    Patrick Hwu
    Amir A. Jazaeri
    Cara Haymaker
    Chantale Bernatchez
    Cancer Immunology, Immunotherapy, 2019, 68 : 1747 - 1757
  • [36] Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC)
    Mousa, Ahmed M.
    Enk, Alexander H.
    Hassel, Jessica C.
    Reschke, Robin
    CELLS, 2024, 13 (19)
  • [37] Single-cell RNA sequencing and cell-cell communication analysis reveal tumor microenvironment associated with chemotherapy responsiveness in ovarian cancer
    Jiang, Xiaoyan
    Chen, Ningxuan
    Wei, Qinglv
    Luo, Xin
    Liu, Xiaoyi
    Xie, Lingcui
    Yi, Ping
    Xu, Jing
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025, 27 (03) : 1000 - 1012
  • [38] Clinical value of serum tumor markers in assessing the efficacy of neoadjuvant chemotherapy in advanced ovarian cancer: single-center prospective clinical study
    Huang, Jing
    Du, Danyi
    Chen, Hailong
    Luo, Deping
    Wang, Qi
    Li, Chan
    Li, Yuanxiang
    Yu, Ying
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [39] Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints
    Fanale, Daniele
    Corsini, Lidia Rita
    Bono, Marco
    Randazzo, Ugo
    Barraco, Nadia
    Brando, Chiara
    Cancelliere, Daniela
    Contino, Silvia
    Giurintano, Ambra
    Magrin, Luigi
    Pedone, Erika
    Perez, Alessandro
    Piraino, Paola
    Pivetti, Alessia
    Di Giovanni, Emilia
    Russo, Tancredi Didier Bazan
    Prestifilippo, Ornella
    Gennusa, Vincenzo
    Pantuso, Gianni
    Russo, Antonio
    Bazan, Viviana
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 193
  • [40] Tumor immune microenvironment changes are associated with response to neoadjuvant chemotherapy and long-term survival benefits in advanced epithelial ovarian cancer: A pilot study
    Cao, Guangming
    Hua, Dingchao
    Li, Jinfeng
    Zhang, Xuefang
    Zhang, Zhiqiang
    Zhang, Bei
    Bei, Ting
    Cui, Lina
    Chen, Shiqing
    Wang, Shuzhen
    Zhu, Lei
    FRONTIERS IN IMMUNOLOGY, 2023, 14